第29届欧洲血液学协会(EHA)年会于2024年6月13日在西班牙马德里正式开幕。作为全世界血液学工作者的盛会,EHA大会主题涵盖了血液学研究的各个方面,每年有来自全球100多个国家的10000余名专业人士与会,分享探讨有关血液学的创新理念及最新科学和临床研究成果。
英文题目:Real-world effectiveness of hetrombopag for cancer therapy-induced thrombocytopenia in cancer patients 英文题目:Safety, pharmacokinetics, and preliminary efficacy of hetrombopag in pediatric patients with aplastic anemia: a pilot study 英文题目:Long-term follow-up results from clinical study of hetrombopag combined with cyclosporine a in the treatment of children with non-severe aplastic anemia 中文题目:海曲泊帕提升接受肝切除术的肝细胞癌患者血小板计数的有效性和安全性:一项随机、安慰剂对照临床研究 英文题目:Efficacy and safety of hetrombopag in increasing platelet counts in patients with hepatocellular carcinoma undergoing hepatectomy: a randomized, placebo-controlled study 英文题目:Efficacy of hetrombopag in treatment of chemotherapy-induced thrombocytopenia in acute myeloid leukemia patients 英文题目:A single-arm, prospective, single-center clinical study on the use of hetrombopag for the prevention of consolidation chemotherapy-induced thrombocytopenia in acute leukemia 通讯作者:张曦 教授 陆军军医大学第二附属医院(新桥医院)
第一作者:张诚 教授 陆军军医大学第二附属医院(新桥医院)
英文题目:Exploratory trial of hetrombopag in the treatment of thrombocytopenia induced by chemoradiotherapy in patients with gynecological malignancies 英文题目:Efficacy and safety of hetrombopag for secondary prevention of chemotherapy-induced thrombocytopenia in patients with gynecological malignancies: a prospective, single-center, single-arm study 英文题目:Combination of chemotherapy and mecapegfilgrastim for hematopoietic stem cell mobilization in lymphoma and multiple myeloma patients: a prospective, open-label, randomized study 英文题目:Efficacy and safety of mecapegfilgrastim in preventing chemotherapy-induced neutropenia in patients with diffuse large B-cell lymphoma 本次EHA大会,恒瑞医药10余项创新药研究将在国际学术舞台精彩亮相,是中国血液学领域研发创新力量的重要展现。作为创新型国际化制药企业,恒瑞医药致力于推动医药创新成果惠及全球患者。目前,公司已有16款1类创新药及4款2类新药在国内获批上市,另有90多个自主创新产品正在临床研发,近300项临床试验在国内外开展。 未来,恒瑞医药将继续坚持“以患者为中心”的理念,重创新,强研发,力争研制出更多更好的新药,服务健康中国,惠及全球患者。 1.https://library.ehaweb.org/eha/#!*menu=6*browseby=3*sortby=2*ce_id=2552
1.本新闻旨在分享学术前沿动态,仅供医疗卫生专业人士基于学术目的参阅,非广告用途。
2.恒瑞医药不推荐任何未被批准的药品、适应症的使用。